Merck & Co. (NYSE:MRK - news) on Thursday suffered a double setback when a federal jury awarded $51 million to a former user of its withdrawn pain medicine Vioxx, and a New Jersey judge threw out a Vioxx verdict that had favored the drug maker and ordered a new trial. The news sent its shares down 5.7 percent, and evened the score between Merck and plaintiffs in Vioxx cases at four victories apiece. The company is facing at least 14,200 other lawsuits from people who say they were harmed by the drug, but Merck vowed to continue defending itself on...